한글목차

아르바클로펜 ER는 바클로펜의 R 이성체인 아르바클로펜의 서방성 제제로, 독자적인 오스모덱스 약물전달 시스템을 활용하여 다발성 경화증에 기인하는 경직 치료제로서 연구되고 있습니다. mGluR5 수용체의 업스트림에 작용하여 억제성 신경 전달을 증가시킵니다. 항경직 작용을 가진 바클로펜의 이성체입니다.

이 회사는 다발성 경화증에 기인하는 경직 징후 및 증상을 완화하기 위해 설계된 후기 단계의 제품 후보인 아르바클로펜 ER 정의 판매 또는 아웃 라이선스의 기회를 모색하고 있으며, 이 제제는 제III상 임상시험을 완료했습니다.

주요 7개국의 아르바클로펜 ER 시장에 대해 조사했으며, 시장의 개요와 2026-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 경직에 대한 아르바클로펜 ER의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제상 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 아르바클로펜 ER 시장 평가

• 경직에 대한 아르바클로펜 ER의 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국에서 경직에 대한 아르바클로펜 ER의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"Arbaclofen ER Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about Arbaclofen ER for spasticity in the seven major markets. A detailed picture of the Arbaclofen ER for spasticity in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Arbaclofen ER for spasticity. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Arbaclofen ER market forecast analysis for spasticity in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in spasticity.

Drug Summary:

Arbaclofen ER is an extended-release formulation of arbaclofen, the R isomer of baclofen that leverages the proprietary for osmodex drug delivery system and is being studied for the treatment of spasticity resulting from multiple sclerosis. It acts upstream of the mGluR5 receptor to increase inhibitory neurotransmission. It is the isomer of baclofen which harbors antispastic activity.

The company is exploring opportunities to sell or out-license late-stage product candidate arbaclofen ER tablets designed to alleviate signs and symptoms of spasticity resulting from multiple sclerosis, for which they have completed Phase III clinical trials.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Arbaclofen ER description, mechanism of action, dosage and administration, research and development activities in spasticity.
• Elaborated details on Arbaclofen ER regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Arbaclofen ER research and development activities in spasticity across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Arbaclofen ER.
• The report contains forecasted sales of Arbaclofen ER for spasticity till 2032.
• Comprehensive coverage of the late-stage emerging therapies for spasticity.
• The report also features the SWOT analysis with analyst views for Arbaclofen ER in spasticity.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Arbaclofen ER Analytical Perspective by DelveInsight

• In-depth Arbaclofen ER Market Assessment

This report provides a detailed market assessment of Arbaclofen ER for spasticity in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

• Arbaclofen ER Clinical Assessment

The report provides the clinical trials information of Arbaclofen ER for spasticity covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for spasticity is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Arbaclofen ER dominance.
• Other emerging products for spasticity are expected to give tough market competition to Arbaclofen ER and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Arbaclofen ER in spasticity.
• Our in-depth analysis of the forecasted sales data of Arbaclofen ER from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Arbaclofen ER in spasticity.

Key Questions

• What is the product type, route of administration and mechanism of action of Arbaclofen ER?
• What is the clinical trial status of the study related to Arbaclofen ER in spasticity and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Arbaclofen ER development?
• What are the key designations that have been granted to Arbaclofen ER for spasticity?
• What is the forecasted market scenario of Arbaclofen ER for spasticity?
• What are the forecasted sales of Arbaclofen ER in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Arbaclofen ER for spasticity?
• Which are the late-stage emerging therapies under development for the treatment of spasticity?

Table of Contents

1. Report Introduction

2. Arbaclofen ER Overview in Spasticity

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Arbaclofen ER Market Assessment

• 5.1. Market Outlook of Arbaclofen ER in Spasticity
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Arbaclofen ER in the 7MM for Spasticity
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Arbaclofen ER in the United States for Spasticity
  • 5.3.2. Market Size of Arbaclofen ER in Germany for Spasticity
  • 5.3.3. Market Size of Arbaclofen ER in France for Spasticity
  • 5.3.4. Market Size of Arbaclofen ER in Italy for Spasticity
  • 5.3.5. Market Size of Arbaclofen ER in Spain for Spasticity
  • 5.3.6. Market Size of Arbaclofen ER in the United Kingdom for Spasticity
  • 5.3.7. Market Size of Arbaclofen ER in Japan for Spasticity

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options